Analyst Price Targets — EDAP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 22, 2026 10:14 am | — | Loop Capital Markets | $10.00 | $4.76 | StreetInsider | Lucid Capital Markets Starts EDAP TMS S.A. (EDAP) at Buy |
| April 9, 2026 1:16 pm | Swayampakula Ramakanth | H.C. Wainwright | $10.00 | $3.36 | TheFly | EDAP TMS price target lowered to $10 from $14 at H.C. Wainwright |
| November 6, 2025 8:09 pm | Michael Sarcone | Jefferies | $2.00 | $1.99 | StreetInsider | EDAP TMS S.A. (EDAP) PT Raised to $2 at Jefferies |
| April 1, 2024 6:24 am | Swayampakula Ramakanth | H.C. Wainwright | $19.00 | $7.35 | TheFly | EDAP TMS price target raised to $19 from $16 at H.C. Wainwright |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for EDAP

Edap Tms NASDAQ: EDAP used its 2026 FocalTherics Investor Day to outline its shift toward becoming a “high-growth, pure-play robotic focal therapy company,” with management emphasizing the company's Focal One robotic high-intensity focused ultrasound, or HIFU, platform for prostate cancer and future indications.

, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy

, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial…

, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of EDAP's Focal One Robotic HIFU and Telix's PSMA PET imaging products in the management of prostate cancer.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EDAP.
U.S. House Trading
No House trades found for EDAP.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
